Current stock page

Financial Data

OCUL Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

OCULOcular Therapeutix, Inc.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 1/10
$6.21−$0.07 (−1.11%)

Latest quote

  • Momentum
    34
  • Value
    41
  • Quality
    42
  • Risk resilience
    36
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$12.87M$13.48M$10.79M$13.25M$14.54M$13.46M$10.7M$17.08M
Gross Profit$11.42M$11.46M$9.46M$11.66M$12.77M$11.52M$9.44M$15.85M
Operating Income-$97.86M-$82.11M-$93.34M-$69.76M-$68.7M-$67.64M-$63.92M-$50.58M
Net Income-$94.78M-$78.76M-$88.61M-$64.65M-$69.42M-$67.81M-$64.05M-$48.39M
EPS-$0.42-$0.35-$0.4-$0.29-$0.38-$0.39-$0.38-$0.29
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$65.62M-$67.27M-$65.99M-$54.25M-$50.73M-$55.24M-$44.67M-$39.43M
Capital Expenditure-$3.03M-$3.37M-$4.66M-$2.84M-$5.99M-$1.25M-$1.93M-$202K
Free Cash Flow-$68.65M-$70.64M-$70.66M-$57.09M-$56.72M-$56.48M-$46.6M-$39.63M
Net Cash Provided By Operating Activities-$65.62M-$67.27M-$65.99M-$54.25M-$50.73M-$55.24M-$44.67M-$39.43M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$605.65M$671.32M$732.53M$808.06M$410.88M$451.33M$405.92M$457.94M
Total Debt$80.01M$79.38M$79.46M$76.97M$77.01M$76.94M$76.22M$75.78M
Cash And Cash Equivalents$530.61M$598.64M$666.7M$737.06M$344.77M$391.13M$349.68M$392.1M
Total Liabilities$164.7M$151.28M$150.96M$153.75M$152.65M$145.42M$139.99M$142.59M
Total Stockholders Equity$440.95M$520.04M$581.57M$654.31M$258.23M$305.92M$265.93M$315.34M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio3.53.633.743.047.766.774.923.16
P/S ratio27.8———————
Debt To Equity0.180.150.140.120.30.250.290.24
Free Cash Flow Yield-17.29%-13.50%-11.07%-10.92%-9.95%-8.66%-11.34%-13.66%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio3.53.633.743.047.766.774.923.16
P/S ratio27.8———————
Return On Equity-74.12%-57.97%-49.95%-40.64%-96.69%-70.85%-72.47%-61.36%
Debt To Equity0.180.150.140.120.30.250.290.24

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-4.25x
Pb3.18x
Revenue Growth Yoy-11.48%
EPS Growth Yoy-10.53%
Gross Margin87.32%
Operating Margin-680.90%
ROE-59.50%
ROIC-62.89%
Debt To Equity0.18
FCF Yield-19.54%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$6.21
Volume2.49M
RSI (14)37.62
MACD-0.37
MACD signal-0.4
MACD histogram0.03
ADX (14)40.36
SMA (50)$7.99
SMA (200)$8.91
ATR (14)$0.45
Historical volatility (annualized)75.15%
Volume (20-day average)2.77M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score36/100
Beta1.39
Annual volatility76.10%
Max Drawdown-61.45%
Sharpe Ratio-0.45
VaR (95%, 1-day)-6.70%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

OCUL Financial Data FAQ

What is Ocular Therapeutix, Inc.'s revenue?

Ocular Therapeutix, Inc.'s revenue is one of the core financial data points for OCUL. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Ocular Therapeutix, Inc.'s revenue growing?

Revenue growth shows whether Ocular Therapeutix, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is OCUL's EPS?

OCUL's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Ocular Therapeutix, Inc.'s net income?

Ocular Therapeutix, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Ocular Therapeutix, Inc. generate?

Free cash flow shows how much cash Ocular Therapeutix, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Ocular Therapeutix, Inc. have?

Cash and debt help frame OCUL's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.